Indivior PLC (INDV.L)

1,385.00 +2.00 (+0.14%) At close: 05:57PM BST

Indivior PLC

10710 Midlothian Turnpike
North Chesterfield, VA 23235
United States
804 379 1090
https://www.indivior.com

Sector(s): Healthcare
Industry: Drug Manufacturers—Specialty & Generic
Full-time employees: 900

Key executives

Name	Title	Pay	Exercised	Year born
Mr. Mark Crossley	CEO & Exec. Director	2.22M	N/A	N/A
Mr. Ryan Preblick	CFO & Exec. Director	1.06M	N/A	N/A
Dr. Christian Heidbreder	Chief Scientific Officer	N/A	N/A	N/A
Mr. Jason Thompson	VP of Investor Relations	N/A	N/A	N/A
Ms. Cynthia Cetani	Chief Integrity & Compliance Officer	N/A	N/A	N/A
Mr. Jeffrey W. Burris	Chief Legal Officer	N/A	N/A	1972
Mr. Jon Fogle	Chief HR Officer	N/A	N/A	N/A
Mr. Richard Simkin	Chief Commercial & Strategy Officer	N/A	N/A	N/A
Mr. Hillel West	Chief Manufacturing & Supply Officer	N/A	N/A	N/A
Ms. Nina DeLorenzo	Chief Global Impact Officer	N/A	N/A	N/A

Amounts are as of 31 December 2021, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in GBp.

Description

Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders. The company's product pipeline focuses on treating opioid use disorder, addiction, and schizophrenia. It markets and promotes SUBLOCADE injection for subcutaneous use; and SUBOXONE sublingual film, SUBOXONE sublingual tablet, and SUBUTEX sublingual tablet, as well as sells legacy products that include Temgesic, Burpex, and Buprenex. The company operates in approximately 40 countries worldwide. Indivior PLC has research collaboration agreement with Addex Therapeutics Ltd. The company was incorporated in 2014 and is headquartered in North Chesterfield, Virginia.

Corporate governance

Indivior PLC’s ISS governance QualityScore as of 1 February 2023 is 6. The pillar scores are Audit: 10; Board: 4; Shareholder rights: 1; Compensation: 5.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.